Mantle Cell Lymphoma Pipeline Outlook 2025: Insights Into Therapies, Research, And Market Potential

DelveInsight's,“ Mantle Cell Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mantle Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Mantle Cell Lymphoma Pipeline? Click here to explore the therapies and trials making headlines @ Mantle Cell Lymphoma Pipeline Outlook Report

Key Takeaways from the Mantle Cell Lymphoma Pipeline Report

• On 09 September 2025, BeiGene announced a study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
• On 08 September 2025, M.D. Anderson Cancer Center conducted a Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma.
• DelveInsight's Mantle Cell Lymphoma Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Mantle Cell Lymphoma treatment.
• The leading Mantle Cell Lymphoma Companies such as AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.
• Promising Mantle Cell Lymphoma Therapies such as Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib , and others.

Want to know which companies are leading innovation in Mantle Cell Lymphoma? Dive into the full pipeline insights @ Mantle Cell Lymphoma Clinical Trials Assessment

The Mantle Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Mantle Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Mantle Cell Lymphoma.

Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by an (11,14) translocation resulting in overexpression of the cyclin D1 (CCND1) gene. The variety of morphologic variants may make this a challenging diagnosis, although some cases are uncomplicated. Many individuals with mantle cell lymphoma may not have symptoms (asymptomatic) during early stages of the disease. However, affected individuals may eventually seek medical attention due to persistent, usually painless, swelling of certain lymph nodes, particularly nodes within the neck and throat region (e.g., Waldeyer's ring).

Mantle Cell Lymphoma Emerging Drugs

• Venetoclax: AbbVie

Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the US and by AbbVie outside of the US. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the US. Currently the product is in Phase III for mantle cell lymphoma.

• Ixazomib: Takeda

Ixazomib belongs to a class of drugs called proteasome inhibitors, which work by blocking the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, ixazomib helps to disrupt the growth and survival of cancer cells. Currently, the product is in the Phase II stage of its development for the treatment of mantle cell lymphoma.

• LP-168: Jiangsu Hansoh Pharmaceutical

LP-168 is a novel drug candidate being explored for the treatment of Mantle Cell Lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma. It is an oral selective inhibitor of Bruton's tyrosine kinase (BTK), which plays a key role in B-cell malignancies. By inhibiting BTK, LP-168 aims to block the survival and proliferation of cancerous B cells, offering a potential therapeutic option for patients with MCL. Early trials suggest promising efficacy, especially in patients who have relapsed or are resistant to current treatments. Currently, the drug is being developed in the Phase II stage of its development for the treatment Mantle Cell Lymphoma.

• PEP07: PharmaEngine

PEP07 is a checkpoint kinase 1 (CHK1) inhibitor which targets the DNA Damage Response (DDR) pathway. CHK1 inhibitors have important functions in the cell's DDR process as it can enhance the damaging effect of cytotoxic therapy on DNA and prevent the self-repair of tumor cells leading to tumor cell deaths. Compared to other competitors targeting the DDR pathway, PEP07 has features such as high kinase selectivity, brain penetrating and oral bioavailability. PEP07 also has demonstrated significant single-agent activity and combination potential with standard treatments in preclinical models. PharmaEngine exercised the option for a Worldwide Exclusive License Agreement for PEP07 from UK-based Sentinel Oncology in September 2022. Currently, the drug is being developed in the Phase I stage of its development for the treatment Mantle Cell Lymphoma.

If you're tracking ongoing Mantle Cell Lymphoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Mantle Cell Lymphoma Treatment Drugs

The Mantle Cell Lymphoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Mantle Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma Treatment.
• Mantle Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Mantle Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mantle Cell Lymphoma market.

Mantle Cell Lymphoma Companies

AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Mantle Cell Lymphoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Mantle Cell Lymphoma Pipeline Report covers it all – check it out now @ Mantle Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Mantle Cell Lymphoma Pipeline Report

• Coverage- Global
• Mantle Cell Lymphoma Companies- AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.
• Mantle Cell Lymphoma Therapies- Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib , and others.
• Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Mantle Cell Lymphoma treatment landscape in this detailed analysis @ Mantle Cell Lymphoma Emerging Drugs and Major Players

Table of Contents